Mgc Pharmaceuticals Ltd (MXC:ASX)

5.0¢

right-arrow Created with Sketch. -0.001 (-1.96%)
MCAP $120.2M
Last trade 16.10pm 22/10/2021 20mins delayed

Latest Announcements

15/10/2021 Price SensitivePSMXCMgc Pharmaceuticals Ltd
12/10/2021MXCMgc Pharmaceuticals Ltd
07/10/2021MXCMgc Pharmaceuticals Ltd
07/10/2021MXCMgc Pharmaceuticals Ltd
07/10/2021MXCMgc Pharmaceuticals Ltd
164
MCap
07/10/2021MXCMgc Pharmaceuticals Ltd
07/10/2021MXCMgc Pharmaceuticals Ltd
07/10/2021 Price SensitivePSMXCMgc Pharmaceuticals Ltd

Company Overview

MGC Pharmaceuticals Limited is an Australia-based biopharma company. The Company is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).

MXC in the news

MGC Pharmaceuticals (MXC) receives an order for more than $4 million for…
MGC Pharmaceuticals’ (MXC) distribution partner, AMC Holdings, orders an initial 1000 units…
MGC Pharmaceuticals (MXC) is granted a permit to import its refractory epilepsy…
MGC Pharmaceuticals (MXC) receives a permit to import its proposed COVID-19 treatment…

Search Previous Announcements